Although many different mechanisms were implicated in tumor-associated immune deficiency, myeloid-derived suppressor cells (MDSC) are now considered as one of the most prominent factors limiting the ability of immune system to control tumor progression. The accumulation of MDSCs has been documented not only in cancer, but also in many other pathological conditions associated with chronic inflammations. MDSCs inhibit the function of T cells and other cells of the immune system through a number of different mechanisms. 1 Morphological and functional heterogeneity is the hallmark of MDSCs. These cells are comprised of myeloid progenitor cells and precursors of macrophages, granulocytes and dendritic cells. Recent studies demonstrated that MDSCs consist of two main subsets: polymorphonuclear (PMN-MDSCs) and monocytic MDSCs (M-MDSCs) 2 . In tumor-free mice, cells with the same phenotype are represented by PMN and inflammatory monocytes, respectively. It was thought that PMN-MDSCs and M-MDSCs are developed alongside separate differentiation pathways (Fig. 1) . Our recent study suggested that this view needs to be revisited. 3 PMN-MDSCs comprise 60~80% of MDSCs in cancer. These cells have a relatively shorter lifespan and lower proliferation ability than M-MDSCs. Even though M-MDSCs are highly proliferative, the expansion of M-MDSCs is barely detectable in cancer. This discrepancy raised the possibility that PMN-MDSCs might be replenished from M-MDSCs. Our data demonstrated that sorted M-MDSCs from tumor-bearing mice were able to acquire polymorphonuclear morphology in the presence of tumor cell-conditioned medium in vitro, or after the adoptive transfer to a tumor-bearing recipient. PMN, generated from M-MDSCs, shared features of PMN-MDSCs, including immune-suppressive activity, a high production of reactive oxygen species and a high myeloperoxidase activity. In contrast, monocytes from tumor-free mice preferentially differentiated into dendritic cells and macrophages. Interestingly, monocytes started to differentiate into PMN cells when tumor explant supernatant was added. These results confirmed previous information that, in non-pathological conditions, monocytes differentiate into dendritic cells or macrophages. However, in a tumor environment, they preferentially differentiated into PMNMDSCs. The dominant accumulation of PMN-MDSCs and the development of PMN-MDSCs from M-MDSCs were also observed in cancer patients.
This process was controlled by loss of the retinoblastoma protein (Rb1) in MDSCs. The Rb1 role in the cell cycle is well established; whereas, its contribution to myeloid cell differentiation is not clear. Recent study demonstrated that the inactivation of Rb1 resulted in profound myeloproliferation. 4 We observed the loss of Rb1 proteins in splenocytes from tumor-bearing mice, which correlated with the expansion of MDSCs. Rb1 expression in PMN-MDSCs was barely detectable, while its high expression was found in M-MDSCs as well as mature myeloid cells from tumor-free mice. We found that bone marrow M-MDSCs and monocytes contained two populations of cells, with high and low presence of Rb1. Several important questions pertinent to this study need to be addressed:
• How is PMN-MDSCs development from granulocyte-macrophage progenitors (GMP) regulated in cancer? Although PMN-MDSCs can be developed from M-MDSCs, they can also be generated from GMP (Fig. 1) . The proportion of PMN-MDSCs differentiated from M-MDSCs or GMP is also not clear. Therefore, the investigation of the differentiation of PMN-MDSCs from GMP will broaden the knowledge of MDSC expansion in cancer.
• What's the role of Rb pocket proteins in MDSCs expansion? The Rb family consists of three genes: Rb1, p107 and p13. Recent study showed that the loss of three Rb family proteins in hematopoietic stem cells resulted in myeloproliferation accompanied by increased apoptosis of lymphoid progenitor cells. 5 However, their roles in myeloid cell development in cancer are not known.
• Is downregulation of Rb1, by itself, sufficient to generate immune-suppressive
